- Conditions
- XXB750 in Healthy Participants
- Interventions
- XXB750, Placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Cypress, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF), or Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
- Interventions
- XXB750, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 3
- States / cities
- Inverness, Florida • Jacksonville, Florida • Saint Paul, Minnesota
- Conditions
- Resistant Hypertension
- Interventions
- XXB750 drug, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 18
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Sacramento, California + 15 more
- Conditions
- Heart Failure
- Interventions
- Placebo, XXB750 Low dose, XXB750 Medium Dose, XXB750 High Dose, Sacubitril/valsartan
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 14
- States / cities
- Dothan, Alabama • Huntsville, Alabama • Inverness, Florida + 11 more